ArticleJournal of experimental & clinical cancer research : CR2026
Targeting serine synthesis pathway to reverse paclitaxel resistance in NSCLC with combination of paclitaxel and anlotinib.
Mengting Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.